General AML

Sangmin Lee | ASH 2018 | Luspatercept in MDS

Cynthia Umukoro , Dec 7, 2018

English & Spanish

General AML

Bruno Paiva | ASH 2018 | The role of MRD in redefining CR in elderly patients with AML

Cynthia Umukoro , Dec 7, 2018

English & German

FLT3

Andreas Burchert | ASH 2018 | Key highlights of the Sormain trial

Cynthia Umukoro , Dec 7, 2018

General AML

ASH 2018 | AMG 330, a BiTE® construct, in patients with relapsed/refractory acute myeloid leukemia

Cynthia Umukoro , Dec 7, 2018

General AML

Laura Michaelis | ASH 2018 | Moving beyond 7 + 3 in acute myeloid leukemia

Cynthia Umukoro Natasha Fort , Dec 6, 2018

General AML,   IDH1/2

Eytan Stein | ASH 2018 | Early results from the Beat AML Master Trial

Cynthia Umukoro , Dec 5, 2018

FLT3

FDA grants approval to gilteritinib (Xospata®) for the treatment of relapsed or refractory acute myeloid leukemia…

Cynthia Umukoro , Nov 29, 2018

FLT3

FDA grants quizartinib priority review for the treatment of relapsed/refractory acute myeloid leukemia…

Cynthia Umukoro , Nov 27, 2018

General AML

MRD-guided preemptive therapy in patients with acute myeloid leukemia – results from the phase II RELAZA2 study

Cynthia Umukoro , Nov 26, 2018

General AML

FDA grants venetoclax (Venclexta®) approval for the treatment of newly diagnosed acute myeloid leukemia

Cynthia Umukoro , Nov 22, 2018